By Steve Dechan
Platform 14 was founded with the sole purpose of introducing and distributing new medical technology in to the UK market. I am exceptionally proud of everything the company has achieved so far, but as they say: the best is yet to come. In 2018 we commenced the process of bringing BioWave to European market. Last year Platform 14 acquired a share in BioWave USA and this year we are on mission to use their flagship product BioWave to revolution pain management in the UK.
What is BioWave? BioWave is a highly effective pain management device, it is currently under application for a CE mark. In layman’s terms the device delivers therapeutic electrical signals through the skin to block pain signals from nerves and this prevents these signals from making their through the central nervous system and reaching the brain. Biowave is patented and is an entirely new piece of technology.
BioWave can be used at home and on the go. It has already been a tremendous success in the USA. Over 100 professional sports teams and 137 college sports programmes in America are currently using the device in addition to countless members of the general public, it has now been approved by all major insurers in the US. In the UK, we’re currently trialling the device with a number of different premiere league football clubs (unfortunately I can’t disclose which ones) but they are loving the results. A recent published clinical trial of 463 patients BioWave demonstrated 8 hours pain free from a single 30 minute treatment and 54% of patients experiencing a reduction in pain medication use.
If you would like to understand a little bit more about the science behind BioWave then keep reading.
BioWave utilises signal mixing technology that delivers two continuously summed, high-frequency alternating current signals through skin into deep tissue through two pads. This creates a new set of signals, one of which is in the form of a low-frequency electrical field between the two pads. The electrical field is thought to change the nerve cells’ membrane potential (hypolarisation), thereby stopping the nerve fibre sending a pain signal through the central nervous system to the brain.
Why do I want to deliver BioWave to patients in the UK? Well first and foremost there is a lot of demand. There are around 28 million adults in the UK living with pain that has lasted for three months or longer. It’s an astonishing figure and it takes a moment to fully absorb what it means.
Around 28 million people in this country are trying to go about their day to day lives, working and caring for loved ones, whilst all the time being in physical pain. Many of these people will have been to seen their GP and may be taking opioids to provide them with some relief. But for those who don’t want to take opioids or can’t I am determined to deliver an alternative treatment option that works. Life is hard enough as it is and physical pain should not be an additional burden.
National Library of Medicine “Prevalence of chronic pain in the UK: a systematic review and meta-analysis of population studies” (National Library of Medicine: London) 2016.